Ken Keller

Daiichi Sankyo has appointed Ken Keller to the newly created role of Chief Commercialization Officer, effective April 1, 2027. He will be responsible for accelerating growth of the company's oncology and specialty medicine business through a new globally integrated Commercialization Unit.

Alongside the new role, Keller will remain a member of the Board of Directors of Daiichi Sankyo Company, Limited, and will continue as Chairman of the Board, President and Chief Executive Officer of Daiichi Sankyo, Inc., the company's US subsidiary. 

He joined the company in 2014 and has led the Global Oncology Business for the past five years, building commercial capabilities in the United States and Europe. From 2016 to 2021 he also served as President and CEO of American Regent, Inc.

The company credited him with advancing its commercial capabilities and with the successful launches of Enhertu and Datroway, its two lead DXd antibody drug conjugates.